A Novel Biologic Therapy for Perennial Allergic Rhinitis
Status:
Completed
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
This is a randomized, parallel-group, double-blind, phase 2, single center, proof-of-concept
study which will evaluate the effect of a preparation of FDA approved allergens (PMA) used as
a sub-cutaneously administered immunotherapy for the management of allergic rhinitis
(perennial and seasonal).